JP5435955B2 - 安定な酵素製剤及びその使用方法 - Google Patents

安定な酵素製剤及びその使用方法 Download PDF

Info

Publication number
JP5435955B2
JP5435955B2 JP2008548072A JP2008548072A JP5435955B2 JP 5435955 B2 JP5435955 B2 JP 5435955B2 JP 2008548072 A JP2008548072 A JP 2008548072A JP 2008548072 A JP2008548072 A JP 2008548072A JP 5435955 B2 JP5435955 B2 JP 5435955B2
Authority
JP
Japan
Prior art keywords
buffer
solution
composition
kit
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008548072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521521A (ja
JP2009521521A5 (https=
Inventor
アミヘイ フリーマン，
ノア ハダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of JP2009521521A publication Critical patent/JP2009521521A/ja
Publication of JP2009521521A5 publication Critical patent/JP2009521521A5/ja
Application granted granted Critical
Publication of JP5435955B2 publication Critical patent/JP5435955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2008548072A 2005-12-27 2006-12-27 安定な酵素製剤及びその使用方法 Expired - Fee Related JP5435955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75340005P 2005-12-27 2005-12-27
US60/753,400 2005-12-27
PCT/IL2006/001492 WO2007074454A2 (en) 2005-12-27 2006-12-27 Stable enzymatic preparations and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009521521A JP2009521521A (ja) 2009-06-04
JP2009521521A5 JP2009521521A5 (https=) 2010-02-12
JP5435955B2 true JP5435955B2 (ja) 2014-03-05

Family

ID=37943776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008548072A Expired - Fee Related JP5435955B2 (ja) 2005-12-27 2006-12-27 安定な酵素製剤及びその使用方法

Country Status (6)

Country Link
US (2) US8197808B2 (https=)
EP (1) EP1965763B1 (https=)
JP (1) JP5435955B2 (https=)
DK (1) DK1965763T3 (https=)
ES (1) ES2763724T3 (https=)
WO (1) WO2007074454A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8197808B2 (en) 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof
JP5213137B2 (ja) * 2006-12-06 2013-06-19 コーネル リサーチ ファウンデーション， インコーポレイテッド 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
ES2759373T3 (es) * 2008-06-12 2020-05-08 Medtronic Xomed Inc Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care
WO2010107488A1 (en) 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN102573794B (zh) * 2009-08-19 2017-03-15 康奈尔大学 供生理注射用的半胱氨酸
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
WO2012030653A2 (en) 2010-08-29 2012-03-08 Vascode Technologies Ltd. A system and methods for multi-tasking in a clientless mobile phone
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
WO2013032745A1 (en) 2011-08-31 2013-03-07 Kci Licensing, Inc. Reduced-pressure treatment and debridement systems and methods
CN104220088A (zh) * 2012-02-02 2014-12-17 柯尔朗恩有限责任公司 酶组合物及其用于创伤愈合的用途
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11364286B2 (en) * 2015-10-14 2022-06-21 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
RU2732224C9 (ru) * 2016-01-31 2021-06-18 Медивунд Лтд. Раноочищающая композиция для лечения ран
WO2017183018A1 (en) * 2016-04-18 2017-10-26 Mediwound Ltd Methods of debridement of chronic wounds
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CA3199921A1 (en) * 2020-11-25 2022-06-02 Steven M. Hernandez Scar treatment composition
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB913203A (en) 1958-12-30 1962-12-19 Swift & Co Enzyme formulations for the production of tenderized meat
US3539451A (en) 1968-05-31 1970-11-10 Castle & Cooke Production of reversibly inactivated papain and ficin
US4307081A (en) 1974-01-08 1981-12-22 Gerold K. V. Klein Enzyme mixture
US4715899A (en) * 1982-10-21 1987-12-29 Subir Chanda Liquid cleaner containing inactivated protease for protein soiled contact lenses
JPH0449299A (ja) * 1990-06-14 1992-02-18 Tosoh Corp 免疫グロブリンフラグメントの精製法
DE4026591B4 (de) 1990-08-23 2005-08-25 Pleva Gmbh Vorrichtung zur Bestimmung der Beladung von Luft mit Dämpfen
JP2665639B2 (ja) * 1992-01-09 1997-10-22 テーオー食品株式会社 安定化されたチオール蛋白分解酵素を含む焼き肉のタレ
US7364565B2 (en) * 2001-07-27 2008-04-29 Ramot At Tel Aviv University Ltd. Controlled enzymatic removal and retrieval of cells
MXPA04004479A (es) * 2001-11-13 2004-08-11 Procter & Gamble Composiciones topicas que contienen enzimas estabilizadas con inhibidores.
US6692726B1 (en) * 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
ATE429897T1 (de) * 2003-10-10 2009-05-15 Cosmedical Aps Haarwuchshemmung
US8197808B2 (en) 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof

Also Published As

Publication number Publication date
US8337837B2 (en) 2012-12-25
DK1965763T3 (da) 2020-02-10
EP1965763B1 (en) 2019-11-06
JP2009521521A (ja) 2009-06-04
US8197808B2 (en) 2012-06-12
EP1965763A2 (en) 2008-09-10
US20120114631A1 (en) 2012-05-10
WO2007074454A3 (en) 2007-09-20
ES2763724T3 (es) 2020-05-29
WO2007074454A2 (en) 2007-07-05
US20090220483A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
JP5435955B2 (ja) 安定な酵素製剤及びその使用方法
IL192483A (en) Distribution tool for single use
JP7853845B2 (ja) Ｅｆｐの治療または低減方法
Monafo et al. Topical therapy for burns
US8343515B2 (en) Perfluorocarbon gel formulations
US20210275471A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
KR101514414B1 (ko) 당뇨병성 족부 궤양의 치료방법
AU7176391A (en) A treatment system and method for wounds and other disorders
US20080020025A1 (en) Composition for wound care and method of using same
CN102223877A (zh) 全氟化碳凝胶
ES2785999T3 (es) Composición para su uso en la preparación de un paciente para cirugía
EP2877188B1 (en) Preparation for treatment of wounds and sores comprising hypochlorite and amino acids
CA2248177A1 (en) Use of protealytic enzymes in the treatment of insect bites
US20150231170A1 (en) Wound healing compositions comprising microspheres
WO2018039420A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JPH01503146A (ja) 身体組織の治療方法および身体組織への医薬の投与方法
US20230338296A1 (en) Devices and methods for delivery of oxygen to a wound
UA64801C2 (uk) Склад з антисептичними, репаративними та болезаспокійливими властивостями
RU2649785C1 (ru) Антисептическая композиция, содержащая поливинилпирролидон и унитиол, применение такой композиции и способ обработки ран с ее использованием
Burba Traumatic foot injuries in horses: surgical management
WO2007143586A2 (en) Composition for wound care and method of using same
Elmenshawy et al. Successful management after ingestion of a potentially fatal dose of inorganic mercuric chloride: A case report
Mang et al. Tumescent Technique in Aesthetic Plastic Surgery with Low Doses of Prilocaine Solution, Part I
JP2693961B2 (ja) 創傷の治癒のための二段階方法及びそれらに使用される水性媒体及び局所性軟膏
EP1776960B1 (en) Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131210

R150 Certificate of patent or registration of utility model

Ref document number: 5435955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees